如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 09939 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的結存(註1) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。 開 拓 藥 業 有 限 公 司 * KINTOR PHARMACEUTICAL LIMITED （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9939） 完成根據一般授權認購新股份 茲提述本公司日期為2025年11月12日的公告（「該公告」），內容有關根據一般授 權發行及認購新股份。除另有界定者外，否則本公告所用詞彙與該公告所界定 者具有相同涵義。 認購事項完成 董事會欣然宣佈，該協議的所有條件已獲達成，而該協議已根據該協議的條款 及條件於2025年11月21日完成。本公司已於2025年11月21日根據該協議的條款 及條件按每股1.64港元向認購人發行及配發30,487,500股新股份。認購股份佔本 公司經認購事項擴大的已發行股本約6.11%。 認購人由中新蘇州工業園區創業投資有限公司全資擁有。本公司的現有 ...

Core Insights - The latest shareholder equity disclosures for several companies, including Ajisen (China) (00538), Zai Lab Limited (09939), Yaoshi Bang (09885), and Kwansei Holdings (01925), were reported on November 21, 2025 [1] Group 1: Shareholder Changes - Ajisen (China) saw a complete divestment by Ren Yuwen, reducing holdings from 95,000 shares to 0 shares, resulting in a holding percentage change from 0.01% to 0% [2] - Zai Lab Limited had an increase in holdings by Tong Youzhi from 52,200,300 shares to 52,500,300 shares, with a holding percentage change from 11.15% to 11.21% [2] - Another increase in Zai Lab Limited was reported for KT International, which raised its holdings from 49,700,300 shares to 50,000,300 shares, changing the holding percentage from 10.62% to 10.68% [2] - Yaoshi Bang experienced a slight increase in holdings by Chen Fei from 8,800,000 shares to 9,000,000 shares, with a holding percentage change from 1.29% to 1.32% [2] - Kwansei Holdings reported an increase in holdings by Tian Dong from 3,895,400 shares to 4,443,400 shares, changing the holding percentage from 0.96% to 1.10% [2]

Group 1 - The latest shareholder equity disclosures for four companies, including 开拓药业-B, 深圳高速公路股份, 固生堂, and 药师帮, were made on November 20, 2025 [1] - 开拓药业-B saw an increase in holdings by Tong Youzhi from 51.50 million shares to 52.20 million shares, representing an increase in ownership percentage from 11.00% to 11.15% [2] - 深圳高速公路股份 experienced a rise in holdings by 江苏云杉资本管理 from 74.75 million shares to 82.23 million shares, with ownership percentage increasing from 10.00% to 11.00% [2] Group 2 - 固生堂's Action Thrive Group Limited increased its holdings from 30.03 million shares to 30.13 million shares, with a slight increase in ownership percentage from 12.97% to 13.01% [2] - 药师帮's 陈飞 raised his holdings from 8.60 million shares to 8.80 million shares, with ownership percentage increasing from 1.26% to 1.29% [2] - 固生堂's 涂志亮 increased his holdings from 81.37 million shares to 81.48 million shares, with ownership percentage slightly rising from 35.14% to 35.19% [2]

Core Viewpoint - 开拓药业-B's stock price increased by over 5%, reaching HKD 2.15, with a trading volume of HKD 5.5445 million [1] Group 1: Company Announcement - 开拓药业-B announced plans to issue 30.4875 million subscription shares to 华圆管理咨询(香港)有限公司 at a subscription price of HKD 1.64 per share, representing a discount of approximately 15.03% compared to the last trading price of HKD 1.93 [1] - The net proceeds from the subscription are expected to be approximately HKD 49.78 million, which will be used for the company's general operating funds and the Phase III clinical trial of KX-826 [1]

Core Viewpoint - 开拓药业-B's stock price increased by over 5%, reaching 2.15 HKD, with a trading volume of 5.5445 million HKD, following the announcement of a share subscription deal [1] Group 1: Share Subscription Announcement - 开拓药业-B plans to issue 30.4875 million subscription shares to 华圆管理咨询(香港)有限公司, a wholly-owned subsidiary of 中新苏州工业园区创业投资有限公司, at a subscription price of 1.64 HKD per share [1] - The subscription price represents a discount of approximately 15.03% compared to the last closing price of 1.93 HKD [1] - The net proceeds from the subscription are expected to be around 49.78 million HKD, which will be used for general working capital and the Phase III clinical trial of KX-826 [1]

Core Viewpoint - The company plans to issue 30.4875 million subscription shares to Huayuan Management Consulting (Hong Kong) Limited at a subscription price of HKD 1.64 per share, representing a discount of approximately 15.03% compared to the last closing price of HKD 1.93 on the Stock Exchange [1] Fundraising and Use of Proceeds - The subscription is expected to raise approximately HKD 49.78 million, which will be used for the company's daily operational funds and the Phase III clinical trial of KX-826 [1]

Core Viewpoint - The company plans to issue 30.4875 million subscription shares at a price of HKD 1.64 per share, representing a discount of approximately 15.03% from the last trading price of HKD 1.93 [1] Group 1 - The net proceeds from the subscription are expected to be approximately HKD 49.78 million [1] - The funds will be used for general working capital and for the Phase III clinical trial of KX-826 [1]

Core Viewpoint - The company plans to issue 30.4875 million subscription shares at a price of HKD 1.64 per share, representing a discount of approximately 15.03% from the last trading price of HKD 1.93 [1] Group 1: Subscription Details - The subscription is aimed at raising approximately HKD 49.78 million, which will be used for general working capital and the Phase III clinical trial of KX-826 [1]

Core Viewpoint - The company, 开拓药业-B (09939.HK), has announced a conditional agreement to issue 30.4875 million shares at a subscription price of HKD 1.64 per share, representing a discount of approximately 15.03% from the last trading price of HKD 1.93 per share [1] Group 1: Subscription Agreement Details - The subscription is with 华圆管理咨询(香港)有限公司, which is wholly owned by 中新苏州工业园区创业投资有限公司 [1] - After the completion of the subscription, the subscriber and 原点创业投资 will collectively hold 49,115,740 shares, equivalent to 10.49% of the company's issued share capital and 9.85% of the enlarged share capital [1] - The shares being subscribed represent approximately 6.51% of the company's issued share capital as of the announcement date [1] Group 2: Financial Implications - The estimated net proceeds from the subscription, after deducting related expenses, are approximately HKD 49.78 million [1] - The company intends to use the net proceeds for general working capital and for the Phase III clinical trial of KX-826 [1]